Role of walnuts in maintaining brain health with age.

J Nutr

USDA-Agricultural Research Services, Human Nutrition Research Center on Aging, Tufts University, Boston, MA.

Published: April 2014

Because of the combination of population growth and population aging, increases in the incidence of chronic neurodegenerative disorders have become a societal concern, both in terms of decreased quality of life and increased financial burden. Clinical manifestation of many of these disorders takes years, with the initiation of mild cognitive symptoms leading to behavioral problems, dementia and loss of motor functions, the need for assisted living, and eventual death. Lifestyle factors greatly affect the progression of cognitive decline, with high-risk behaviors including unhealthy diet, lack of exercise, smoking, and exposure to environmental toxins leading to enhanced oxidative stress and inflammation. Although there exists an urgent need to develop effective treatments for age-related cognitive decline and neurodegenerative disease, prevention strategies have been underdeveloped. Primary prevention in many of these neurodegenerative diseases could be achieved earlier in life by consuming a healthy diet, rich in antioxidant and anti-inflammatory phytochemicals, which offers one of the most effective and least expensive ways to address the crisis. English walnuts (Juglans regia L.) are rich in numerous phytochemicals, including high amounts of polyunsaturated fatty acids, and offer potential benefits to brain health. Polyphenolic compounds found in walnuts not only reduce the oxidant and inflammatory load on brain cells but also improve interneuronal signaling, increase neurogenesis, and enhance sequestration of insoluble toxic protein aggregates. Evidence for the beneficial effects of consuming a walnut-rich diet is reviewed in this article.

Download full-text PDF

Source
http://dx.doi.org/10.3945/jn.113.184838DOI Listing

Publication Analysis

Top Keywords

brain health
8
cognitive decline
8
role walnuts
4
walnuts maintaining
4
maintaining brain
4
health age
4
age combination
4
combination population
4
population growth
4
growth population
4

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!